跳轉至內容
Merck
  • Dietary corosolic acid ameliorates obesity and hepatic steatosis in KK-Ay mice.

Dietary corosolic acid ameliorates obesity and hepatic steatosis in KK-Ay mice.

Biological & pharmaceutical bulletin (2008-04-02)
Kotaro Yamada, Masaya Hosokawa, Chizumi Yamada, Rie Watanabe, Shimpei Fujimoto, Hideya Fujiwara, Masaru Kunitomo, Toshihiro Miura, Tetsuo Kaneko, Kinsuke Tsuda, Yutaka Seino, Nobuya Inagaki
摘要

Corosolic acid (CRA), a constituent of Banaba leaves, has been reported to exert anti-hypertension, anti-hyperinsulinemia, anti-hyperglycemia, and anti-hyperlipidemia effects as well as to induce anti-inflammatory and anti-oxidative activities. The aim of this study was to investigate the inhibitory effects of CRA on the development of obesity and hepatic steatosis in KK-Ay mice, a genetically obese mouse model. Six-week-old KK-Ay mice were fed a high fat diet for 9 weeks with or without 0.023% CRA. Nine-week CRA treatment resulted in 10% lower body weight and 15% lower total fat (visceral plus subcutaneous fat) mass than in control mice. CRA treatment reduced fasting plasma levels of glucose, insulin, and triglyceride by 23%, 41%, and 22%, respectively. The improved insulin sensitivity in CRA-treated mice may be due on part to the increased plasma adiponectin and white adipose tissue (WAT) AdipoR1 levels. In addition, CRA treatment increased the expression of peroxisome proliferator-activated receptor (PPAR) alpha in liver and PPAR gamma in WAT. This is the first study to show that CRA treatment can contribute to reduced body weight and amelioration of hepatic steatosis in mice fed a high fat diet, due in part to increased expression of PPAR alpha in liver and PPAR gamma in WAT.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
Corosolic acid from Lagerstroemia speciosa, ≥98% (HPLC)